$3 million to fight rare cancers
26 November, 2015The Stafford Fox Medical Research Foundation will support the Walter and Eliza Hall Institute in its development of new strategies for diagnosing and treating patients with rare cancers.
ANU to host cognitive health research centre
25 November, 2015ANU has been awarded $2.5 million in the latest NHMRC funding round to host a new Centre of Research Excellence on Cognitive Health.
$9 million to treat heart failure and peanut allergies
23 November, 2015Medical technology companies Cardiora and Aravax have been awarded $9 million in venture capital funding from the Medical Research Commercialisation Fund to develop novel treatments for heart failure and peanut allergies respectively.
Mutant MYC inhibited by Phylogica
16 November, 2015Phylogica has announced the inhibition of the mutant gene MYC — which many cancers depend on for their survival — in an animal model.
Australia's biggest ageing study just got better
13 November, 2015Enhancements to the Sax Institute's 45 and Up Study will help drive research into the genetic causes of various diseases, as well as to build predictive models on the risk of disease.
Lupus: in search of the wolf
12 November, 2015 by Graeme O’NeillA three-year-old patient, and a crucial discovery by Professor Carola Vinuesa's ANU research team, will transform diagnosis and treatment of lupus.
Balnaves Foundation funds two more child cancer researchers
12 November, 2015The Balnaves Foundation has awarded two Children's Cancer Institute Australia researchers $100,000 each to explore uncharted territory in childhood cancer.
Blocking neuroblastoma
09 November, 2015Scientists have identified a critical molecular 'feedback loop' that helps initiate and drive neuroblastoma — as well as a drug that has the potential to stop it.
Accelerating the search for an HIV vaccine
06 November, 2015The European AIDS Vaccine Initiative (EAVI2020) is a €23 million program to speed up the search for an effective HIV vaccine.
Viralytics and MSD collaborate on combination cancer trial
06 November, 2015A new clinical trial will evaluate the combination of Viralytics' investigational cancer immunotherapy, CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.
Fusion drug achieves tumour reduction
05 November, 2015Associate Professor Pilar Blancafort has conducted an expanded study to show that the biologics drug Omomyc, fused to a cell-penetrating Phylomer (1746), can be used to treat cancer.
Protein for progressing autoimmune diseases identified
02 November, 2015Researchers have identified the key protein involved in driving the progression of multiple sclerosis (MS) and other autoimmune diseases through the body's 'super-inflammatory' immune response.
Where sleeping malaria parasites lie
02 November, 2015 by Graeme O'NeillA study of malaria infection, illness and transmission rates among children in Papua New Guinea has yielded a therapeutic strategy that could quell or even eliminate infections by two of the most persistent malaria parasites: Plasmodium vivax and Plasmodium ovale.
Cancer vaccine trial underway
28 October, 2015Regeneus has announced that the first patient has been enrolled and treated in a clinical trial of the company's autologous tumour vaccine, RGSH4K.
Antibody technology as a cancer imaging agent
23 October, 2015Minomic International will next year launch a human study of its monoclonal antibody technology as an imaging agent to detect prostate, pancreatic and bladder cancers.
